Knowledge Hub

Insulin Market In The US And Europe to grow at a CAGR of 6.17% during the period 2016-2020.

Press Release   •   May 16, 2016 09:01 EDT

Description

About Insulin

Beta cells of the pancreas produce insulin, a hormone that regulates blood glucose levels, by stimulating cells to absorb glucose from the blood. In the cells, glucose is converted into energy, which is used by tissues and muscles to perform their physiological functions. This process is restricted in people with diabetes, resulting in the accumulation of glucose in the blood. This condition is known as hyperglycemia; it damages body tissues over a period, leading to life-threatening health complications such as diabetic retinopathy and diabetic nephropathy. In type 1 diabetes or gestational diabetes, the immune system attacks the pancreatic cells, resulting in little or no insulin production. In type 2 diabetes, the body does not produce sufficient insulin to regulate blood glucose levels. In both type 1 and type 2 diabetes, the individual requires daily doses of insulin along with other medications, depending on the condition. Different types of insulin products, such as human insulin and insulin analogs, are available for insulin replacement therapy.

Technavios analysts forecast the Insulin Market in the US and Europe to grow at a CAGR of 6.17% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the insulin market in the US and Europe for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the branded drugs during the forecast period.

The market is divided into the following segments based on geography:

US

Europe

Technavio's report, Insulin Market in the US and Europe 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Download Detail Report With Complete TOC at: http://www.marketresearchreports.biz/sample/sample/717642

Key vendors

Sanofi

Novo Nordisk

Eli Lilly

Other prominent vendors

Adocia

Biocon

Biodel

Biogenomics

Boehringer Ingelheim

Dance Biopharm

Diasome Pharmaceuticals

Exsulin

Generex

Lexicon Pharmaceuticals

Ligand Pharmaceuticals

MannKind

Macrogenics

Merck

Melior Pharmaceuticals

Metabolic Solutions Development Company

NGM Biopharmaceuticals

NuSirt Biopharma

Oramed Pharmceuticals

PhaseBio Pharmaceuticals

Pfizer

Thermalin Diabetes

Tolerion

VeroScience

vTv Therapeutics

Wockhardt

XOMA

Market driver

Advances in insulin delivery technology

For a full, detailed list, view our report

Market challenge

Complexity of insulin production

For a full, detailed list, view our report

Market trend

Increasing price of insulin drugs

For a full, detailed list, view our report

Key questions answered in this report

What will the market size be in 2020 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?